Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28527020 | 0.82 | HDAC8 (0.57) | MEN1KMT2ACA1CA2HDAC8 | |
| SCHEMBL694391 | 0.81 | HDAC3 (0.54) | CA1CA2HDAC8MAPTRXFP1 | |
| SCHEMBL29488493 | 0.81 | HDAC3 (0.54) | CA1CA2HDAC8MAPTRXFP1 | |
| SCHEMBL2655435 | 0.80 | FPR3 (0.41) | MEN1KMT2ACA1CA2HDAC8 | |
| SCHEMBL3864187 | 0.80 | GLS (0.43) | MEN1KMT2ACA2GAAHPGD | |
| SCHEMBL21643351 | 0.80 | LMNA (0.50) | MEN1KMT2AMAPTHPGD | |
| SCHEMBL4085443 | 0.79 | F2R (0.57) | PTPRCMAPTHPGDTP53 | |
| SCHEMBL17094866 | 0.79 | MAPT (0.45) | MEN1KMT2AHDAC8GAAMAPT | |
| SCHEMBL2984278 | 0.79 | MAP4K4 (0.48) | MEN1KMT2AGAAHPGD | |
| SCHEMBL6313118 | 0.78 | MEN1 (0.47) | MEN1KMT2ACA1CA2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585517-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004062663-A1 | USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | MEN1 733/4885KMT2A 2473/4885CA1 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.